Catherine Derington

Catherine Derington, PharmD, MS

Languages spoken: English

Academic Information

Departments Primary - Population Health Sciences

Academic Office Information

catherine.derington@utah.edu

Board Certification

  • Board of Pharmacy Specialties (Sub: Ambulatory Care Pharmacy)

Research Interests

  • Improving Health Outcomes by Optimizing Cardiovascular Medication Use
  • Generating Evidence to Improve Patient Care from Rigorous Pharmacoepidemiology Studies
  • Validating Medication Exposures in Secondary Data

I am a formally trained clinical pharmacist, Research Assistant Professor, and Early-Stage Investigator. I have training in clinical pharmacy, pharmacoepidemiology, and health outcomes from the University of Colorado, The Ohio State University, and Kaiser Permanente Colorado. As a clinical pharmacist, I observed first-hand the challenges that patients face when navigating the US health care system, particularly those dealing with chronic diseases or from vulnerable populations. When barriers to medication access or adherence are present, care gaps develop that adversely impact health. I have led or published projects identifying gaps in cardiovascular medication use, evaluating the impact of cardiovascular medications and intensive BP treatment on health outcomes and population health, and validating algorithms or exposures in secondary data sources. To this end, I collaborate closely with Dr. Adam Bress and Dr. Jordan King on their NIH-funded research programs. I have experience working with data from consented cohorts (e.g., REGARDS, National Health and Nutrition Examination Surveys), clinical trials (e.g., Systolic Blood Pressure Intervention Trial), and electronic health records/administrative claims (e.g., Kaiser Permanente, the Veterans Health Administration).

Research Statement

It is my overarching career goal to streamline the delivery of cardiovascular care in the US to prevent cardiovascular disease-related morbidity and mortality. I am passionate about developing creative, sustainable solutions to deliver optimal care for patients today and in future generations.

Education History

Graduate Training University of Colorado Anschutz Medical Campus
 MS
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences
 Research Fellow
Residency The Ohio State University Wexner Medical Center
 Resident
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences
 PharmD
Undergraduate University of Colorado Anschutz Medical Campus
 BS

Selected Publications

Journal Article

  1. Bryan AS, Moran AE, Mobley CM, Derington CG, Rodgers A, Zhang Y, Fontil V, Shea S, Bellows BK (2023). Cost-effectiveness analysis of initial treatment with single-pill combination antihypertensive medications. J Hum Hypertens, 37(11), 985-992.
  2. King JB, Berchie RO, Derington CG, Marcum ZA, Scharfstein DO, Greene TH, Herrick JS, Jacobs JA, Zheutlin AR, Bress AP, Cohen JB (2023). New Users of Angiotensin II Receptor Blocker-Versus Angiotensin-Converting Enzyme Inhibitor-Based Antihypertensive Medication Regimens and Cardiovascular Disease Events: A Secondary Analysis of ACCORD-BP and SPRINT. J Am Heart Assoc, 12(17), e030311.
  3. Zheutlin AR, Jacobs JA, Derington CG, Chaitoff A, Navar AM, Bress AP (2023). Age-based disparities in statin use for primary prevention in US adults: National Health and Nutrition Examination Surveys 2013-2020. J Clin Lipidol.
  4. Derington CG, Bress AP, Berchie RO, Herrick JS, Shen J, Ying J, Greene T, Tajeu GS, Sakhuja S, Ruiz-Negrn N, Zhang Y, Howard G, Levitan EB, Muntner P, Safford MM, Whelton PK, Weintraub WS, Moran AE, Bellows BK (2023). Estimated Population Health Benefits of Intensive Systolic Blood Pressure Treatment Among SPRINT-Eligible US Adults. Am J Hypertens, 36(9), 498-508.
  5. King JB, Derington CG, Herrick JS, Jacobs JA, Zheutlin AR, Conroy MB, Cushman WC, Bress AP (2023). Single-Pill Combination Product Availability of the Antihypertensive Regimens Used for Intensive Systolic Blood Pressure Treatment in the Systolic Blood Pressure Intervention Trial. Hypertension, 80(8), 1749-1758.
  6. Derington CG, Goodrich GK, Xu S, Clark NP, Reynolds K, An J, Witt DM, Smith DH, OKeeffe-Rosetti M, Lang DT, Ho PM, Cheetham TC, Comer AC, King JB (2023). Association of Direct Oral Anticoagulation Management Strategies With Clinical Outcomes for Adults With Atrial Fibrillation. JAMA Netw Open, 6(7), e2321971.
  7. Zheutlin AR, Addo DK, Jacobs JA, Derington CG, Herrick JS, Greene T, Stulberg EL, Berlowitz DR, Williamson JD, Pajewski NM, Supiano MA, Bress AP (2023). Evidence for Age Bias Contributing to Therapeutic Inertia in Blood Pressure Management: A Secondary Analysis of SPRINT. Hypertension, 80(7), 1484-1493.
  8. Derington CG, Bress AP, Herrick JS, Jacobs JA, Zheutlin AR, Berchie RO, Conroy MB, Cushman WC, King JB (2023). Antihypertensive Medication Regimens Used by US Adults With Hypertension and the Potential for Fixed-Dose Combination Products: The National Health and Nutrition Examination Surveys 2015 to 2020. J Am Heart Assoc, 12(11), e028573.
  9. Jaeger BC, Chen L, Foti K, Hardy ST, Bress AP, Kane SP, Huang L, Herrick JS, Derington CG, Poudel B, Christenson A, Colantonio LD, Muntner P (2023). Hypertension Statistics for US Adults: An Open-Source Web Application for Analysis and Visualization of National Health and Nutrition Examination Survey Data. Hypertension, 80(6), 1311-1320.
  10. Jacobs JA, Addo DK, Zheutlin AR, Derington CG, Essien UR, Navar AM, Hernandez I, Lloyd-Jones DM, King JB, Rao S, Herrick JS, Bress AP, Pandey A (2024). Prevalence of Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease by Race, Ethnicity, and 10-Year Disease Risk in the US: National Health and Nutrition Examination Surveys, 2013 to March 2020. JAMA Cardiol, 8(5), 443-452.
  11. Ghazi L, Shen J, Ying J, Derington CG, Cohen JB, Marcum ZA, Herrick JS, King JB, Cheung AK, Williamson JD, Pajewski NM, Bryan N, Supiano M, Sonnen J, Weintraub WS, Greene TH, Bress AP (2023). Identifying Patients for Intensive Blood Pressure Treatment Based on Cognitive Benefit: A Secondary Analysis of the SPRINT Randomized Clinical Trial. JAMA Netw Open, 6(5), e2314443.
  12. Derington CG, Bress AP, Moran AE, Weintraub WS, Herrick JS, Cushman WC, Kronish IM, Stults B, Shimbo D, Muntner P, Greene T, Bates JT, Chang TI, Katz LA, Rehman SU, Roumie CL, Tamariz L, King JB (2022). Antihypertensive Medication Regimens Used in the Systolic Blood Pressure Intervention Trial. Hypertension, 80(3), 590-597.
  13. Zheutlin AR, Derington CG, Herrick JS, Rosenson RS, Poudel B, Safford MM, Brown TM, Jackson EA, Woodward M, Reading S, Orroth K, Exter J, Virani SS, Muntner P, Bress AP (2022). Lipid-Lowering Therapy Use and Intensification Among United States Veterans Following Myocardial Infarction or Coronary Revascularization Between 2015 and 2019. Circ Cardiovasc Qual Outcomes, 15(12), e008861.
  14. Cohen JB, Marcum ZA, Zhang C, Derington CG, Greene TH, Ghazi L, Herrick JS, King JB, Cheung AK, Bryan N, Supiano MA, Sonnen JA, Weintraub WS, Scharfstein D, Williamson J, Pajewski NM, Bress AP, Systolic Blood Pressure Intervention Trial SPRINT Research Group (2022). Risk of Mild Cognitive Impairment or Probable Dementia in New Users of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors: A Secondary Analysis of Data From the Systolic Blood Pressure Intervention Trial (SPRINT). JAMA Netw Open, 5(7), e2220680.
  15. Zheutlin AR, Derington CG, King JB, Berchie RO, Herrick JS, Dixon DL, Cohen JB, Shimbo D, Kronish IM, Saseen JJ, Muntner P, Moran AE, Bress AP (2021). Factors associated with antihypertensive monotherapy among US adults with treated hypertension and uncontrolled blood pressure overall and by race/ethnicity, National Health and Nutrition Examination Survey 2013-2018. Am Heart J, 248, 150-159.
  16. Derington CG, Bress AP, Herrick JS, Fan W, Wong ND, Andrade KE, Johnson J, Philip S, Abrahamson D, Jiao L, Bhatt DL, Weintraub WS (2022). The potential population health impact of treating REDUCE-IT eligible US adults with Icosapent Ethyl. Am J Prev Cardiol, 10, 100345.
  17. Weintraub WS, Bhatt DL, Zhang Z, Dolman S, Boden WE, Bress AP, King JB, Bellows BK, Tajeu GS, Derington CG, Johnson J, Andrade K, Steg PG, Miller M, Brinton EA, Jacobson TA, Tardif JC, Ballantyne CM, Kolm P (2022). Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment. JAMA Netw Open, 5(2), e2148172.
  18. Zheutlin AR, Mondesir FL, Derington CG, King JB, Zhang C, Cohen JB, Berlowitz DR, Anstey DE, Cushman WC, Greene TH, Ogedegbe O, Bress AP (2022). Analysis of Therapeutic Inertia and Race and Ethnicity in the Systolic Blood Pressure Intervention Trial: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open, 5(1), e2143001.
  19. Marcum ZA, Cohen JB, Zhang C, Derington CG, Greene TH, Ghazi L, Herrick JS, King JB, Cheung AK, Bryan N, Supiano MA, Sonnen JA, Weintraub WS, Williamson J, Pajewski NM, Bress AP, Systolic Blood Pressure Intervention Trial SPRINT Research Group (2022). Association of Antihypertensives That Stimulate vs Inhibit Types 2 and 4 Angiotensin II Receptors With Cognitive Impairment. JAMA Netw Open, 5(1), e2145319.
  20. Smith SM, Desai RA, Walsh MG, Nilles EK, Shaw K, Smith M, Chamberlain AM, Derington CG, Bress AP, Chuang CH, Ford DE, Taylor BW, Chandaka S, Patel LP, McClay J, Priest E, Fuloria J, Doshi K, Ahmad FS, Viera AJ, Faulkner M, OBrien EC, Pletcher MJ, Cooper-DeHoff RM (2022). Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and COVID-19-related outcomes: A patient-level analysis of the PCORnet blood pressure control lab. Am Heart J Plus, 13, 100112.
  21. Colvin CL, Poudel B, Bress AP, Derington CG, King JB, Wen Y, Chen L, Bittner V, Brown TM, Monda KL, Mues KE, Rosenson RS, Jackson EA, Muntner P, Colantonio LD (2021). Race/ethnic and sex differences in the initiation of non-statin lipid-lowering medication following myocardial infarction. J Clin Lipidol, 15(5), 665-673.
  22. Bress AP, Greene T, Derington CG, Shen J, Xu Y, Zhang Y, Ying J, Bellows BK, Cushman WC, Whelton PK, Pajewski NM, Reboussin D, Beddu S, Hess R, Herrick JS, Zhang Z, Kolm P, Yeh RW, Basu S, Weintraub WS, Moran AE, SPRINT Research Group (2021). Patient Selection for Intensive Blood Pressure Management Based on Benefit and Adverse Events. J Am Coll Cardiol, 77(16), 1977-1990.
  23. Derington CG, Cohen JB, Mohanty AF, Greene TH, Cook J, Ying J, Wei G, Herrick JS, Stevens VW, Jones BE, Wang L, Zheutlin AR, South AM, Hanff TC, Smith SM, Cooper-DeHoff RM, King JB, Alexander GC, Berlowitz DR, Ahmad FS, Penrod MJ, Hess R, Conroy MB, Fang JC, Rubin MA, Beddhu S, Cheung AK, Xian W, Weintraub WS, Bress AP (2021). Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans. PLoS One, 16(4), e0248080.
  24. Derington CG, Colantonio LD, Herrick JS, Cook J, King JB, Rosenson RS, Poudel B, Monda KL, Navar AM, Mues KE, Stevens VW, Nelson RE, Vanneman ME, Muntner P, Bress AP (2021). Factors Associated With PCSK9 Inhibitor Initiation Among US Veterans. J Am Heart Assoc, 10(8), e019254.
  25. Derington CG, Mueller SR, Glanz JM, Binswanger IA (2020). Identifying naloxone administrations in electronic health record data using a text-mining tool. Subst Abus, 42(4), 806-812.
  26. Derington CG, King JB, Delate T, Botts SR, Kroehl M, Kao DP, Trinkley KE (2020). Twice-daily versus once-daily lisinopril and losartan for hypertension: Real-world effectiveness and safety. PLoS One, 15(12), e0243371.
  27. Derington CG, Lopez BR, Weber RJ, Tubbs CR (2019). Comparison of 3 Surveillance Methods to Detect Potential Controlled Substance Diversion in an Academic Medical Center. Hosp Pharm, 55(5), 323-331.
  28. Bhat S, Derington CG, Trinkley KE (2020). Clinicians' Values and Preferences for Medication Adherence and Cost Clinical Decision Support in Primary Care: A Qualitative Study. Appl Clin Inform, 11(3), 405-414.
  29. Derington CG, Heath LJ, Kao DP, Delate T (2020). Validation of algorithms to identify elective percutaneous coronary interventions in administrative databases. PLoS One, 15(4), e0231100.
  30. Derington CG, King JB, Herrick JS, Shimbo D, Kronish IM, Saseen JJ, Muntner P, Moran AE, Bress AP (2020). Trends in Antihypertensive Medication Monotherapy and Combination Use Among US Adults, National Health and Nutrition Examination Survey 2005-2016. Hypertension, 75(4), 973-981.
  31. Derington CG, Benavides N, Delate T, Fish DN (2020). Multiple-Dose Oral Fosfomycin for Treatment of Complicated Urinary Tract Infections in the Outpatient Setting. Open Forum Infect Dis, 7(2), ofaa034.
  32. Owlia M, Dodson JA, King JB, Derington CG, Herrick JS, Sedlis SP, Crook J, DuVall SL, LaFleur J, Nelson R, Patterson OV, Shah RU, Bress AP (2019). Angina Severity, Mortality, and Healthcare Utilization Among Veterans With Stable Angina. J Am Heart Assoc, 8(15), e012811.
  33. Derington CG, Gums TH, Bress AP, Herrick JS, Greene TH, Moran AE, Weintraub WS, Kronish IM, Morisky DE, Trinkley KE, Saseen JJ, Reynolds K, Bates JT, Berlowitz DR, Chang TI, Chonchol M, Cushman WC, Foy CG, Herring CT, Katz LA, Krousel-Wood M, Pajewski NM, Tamariz L, King JB, SPRINT Research Group (2019). Association of Total Medication Burden With Intensive and Standard Blood Pressure Control and Clinical Outcomes: A Secondary Analysis of SPRINT. Hypertension, HYPERTENSIONAHA11912907.

Review

  1. An J, Derington CG, Luong T, Olson KL, King JB, Bress AP, Jackevicius CA (2020). Fixed-Dose Combination Medications for Treating Hypertension: A Review of Effectiveness, Safety, and Challenges. [Review]. Curr Hypertens Rep, 22(11), 95.
  2. Derington CG, Cohen JB, Bress AP (2020). Restoring the upward trend in blood pressure control rates in the United States: a focus on fixed-dose combinations. [Review]. J Hum Hypertens, 34(9), 617-623.
  3. Derington CG, King JB, Bryant KB, McGee BT, Moran AE, Weintraub WS, Bellows BK, Bress AP (2019). Cost-Effectiveness and Challenges of Implementing Intensive Blood Pressure Goals and Team-Based Care. [Review]. Curr Hypertens Rep, 21(12), 91.

Letter

  1. Mobley CM, Bryan AS, Moran AE, Derington CG, Zhang Y, Bellows BK (2023). Fixed-Dose Combination Medication Use Among US Adults With Hypertension: A Missed Opportunity. [Letter to the editor]. J Am Heart Assoc, 12(4), e027486.